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The adaptor protein TRAF3 restrains B cell activating factor receptor (BAFFR) and CD40-
mediated activation of the NF-κB2 pathway in B cells. Mice lacking TRAF3 specifically in B
cells revealed the critical role of TRAF3 in restraining homeostatic B cell survival. Further-
more, loss-of-function mutations of the traf3 gene have been associated with human B
cell malignancies, especially multiple myeloma (MM). It has been proposed that receptor-
induced TRAF3 degradation leads to stabilization of the NF-κB inducing kinase (NIK), and
subsequent NF-κB2 activation. However, it is unclear how receptor-mediatedTRAF3 degra-
dation or loss-of-function contributes to B cell-specific NF-κB2 activation. In the current
study, we employed two complementary models to address this question. One utilized a
mutant traf3 gene found in a human MM-derived cell line called LP1.The LP1 mutantTRAF3
protein lacks the TRAF-N and TRAF-C domains. Consistent with the paradigm described,
expression of LP1TRAF3 in B cells promoted higher basal levels of NF-κB2 activation com-
pared to Wt TRAF3. However, LP1 did not associate with TRAF2, CD40, or BAFFR, and no
LP1 degradation was observed following receptor engagement. Interestingly, LP1 showed
enhanced NIK association. Thus, TRAF3 degradation becomes dispensable to activate NF-
κB2 when it is unable to associate with TRAF2. In a second model, we examined several
mutant forms of BAFFR that are unable to induce NF-κB2 activation in B cells. Signaling to
B cells by each of these BAFFR mutants, however, induced levels of TRAF3 degradation
similar to those induced by Wt BAFFR. Thus, in B cells, receptor-mediated TRAF3 degra-
dation is not sufficient to promote NF-κB2 activation. We thus conclude that there is not
a simple linear relationship in B lymphocytes between relative levels of cellular TRAF3,
induced TRAF3 degradation, NIK activation, and NF-κB2 activation.
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INTRODUCTION
Tumor necrosis factor receptor (TNFR) associated factor 3
(TRAF3) is an important adaptor molecule shown to regulate NF-
κB2 activation induced by the TNFR superfamily molecules CD40
and B cell activating factor receptor (BAFFR), as well as other
immune receptors (1–3). In B lymphocytes, CD40 and BAFFR-
mediated signaling is important for regulation of maturation, sur-
vival, Ig class switch recombination, and antibody production (4,
5). Engagement of BAFFR with BAFF or interaction between CD40
and its ligand CD154 triggers the non-canonical NF-κB or NF-
κB2 pathway [reviewed in Ref. (6)]. TRAF3 negatively regulates
NF-κB2 activation (7, 8), and mouse B cells deficient in TRAF3
have substantially enhanced survival, which correlates with con-
stitutive activation of the NF-κB2 pathway (9, 10). Understanding
how TRAF3 regulates both NF-κB2 activation and homeostatic B
cell survival is thus of great importance.
The NF-κB2 pathway is tightly regulated at steady state, and
dysregulation of the pathway is frequently observed in hema-
tological malignancies (11, 12). Gain or loss-of-function muta-
tions of genes encoding key signaling molecules implicated in the
NF-κB2 pathway have been observed in such tumors. In particu-
lar, mutations in NF-κB inducing kinase (NIK), TRAF3, TRAF2,
and cellular inhibitors of apoptosis 1 and 2 (cIAP1, cIAP2) are
highly associated with human multiple myeloma (MM) and MM-
derived cell lines. Loss-of-function mutations of the traf3 gene
have been identified in 9–17% of MM patient cohorts (13, 14).
Such mutations have also been identified in different subtypes
of B cell lymphoma and Waldenström’s macroglobulinemia (15–
17). Consistent with this, a portion of older mice deficient in
TRAF3 specifically in B cells develop B cell lymphomas (18). Taken
together, these studies provide strong evidence that loss or reduced
expression of TRAF3 contributes to B cell malignancies.
A widely held paradigm suggests that the physical associa-
tion between TRAF3, TRAF2, and NIK allows the TRAF2-cIAP
E3 ubiquitin ligase complex to polyubiquitinate NIK (19, 20).
This promotes proteasome-mediated degradation of NIK, and
by so doing, restrains NF-κB2 activation (21). Engagement of
CD40 or BAFFR on B cells is known to recruit TRAFs 2 and 3
to the plasma membrane lipid-raft compartment (22, 23). This
recruitment initiates TRAF2-mediated polyubiquitination of both
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TRAFs 2 and 3, and their subsequent proteasome-mediated degra-
dation (22, 24, 25). The paradigm mentioned above posits that
this receptor-mediated TRAF3 degradation allows NIK stabiliza-
tion, and thus NF-κB2 activation (26, 27). However, it remains
unclear whether TRAF3 degradation is necessary and sufficient
for NF-κB2 activation, in response to CD40 and BAFFR signal-
ing, in B lymphocytes. The present study was designed to address
this important mechanistic question. Utilizing two complemen-
tary approaches, we found that association between TRAFs 2 and 3
is important for CD40 and BAFFR-mediated TRAF3 degradation.
However, degradation of endogenous TRAF3 was neither suffi-
cient nor always required to induce CD40 or BAFFR-mediated
activation of NF-κB2 in B cells.
MATERIALS AND METHODS
MICE
A/J, BAFFR−/−, and Bcl2 transgenic (tg) mice with A/J congenic
backgrounds were kindly provided by Dr. Colleen Hayes (Univer-
sity of Wisconsin, Madison, WI, USA). A/WySnJ mice, also on the
A/J genetic background, were purchased from Jackson Laboratory
(Bar Harbor, ME, USA). A/J, A/WySnJ, and BAFFR−/− mice were
bred with Bcl2 tg mice to circumvent mature B cell developmental
defects in A/WySnJ and BAFFR−/−mice (28, 29). All mice had one
allele of the Bcl2 transgene, and were used at 10–12 weeks of age as
a source of B cells for experiments. Mice were maintained under
pathogen-free conditions at the University of Iowa. Use of mice in
this study was according to a protocol approved by The University
of Iowa Animal Care and Use Committee.
CELL LINES
The mouse B cell lines M12.4.1 (30), CH12.LX, and its TRAF3-
deficient subclones have been previously described (31, 32). B cell
lines stably transfected with hybrid human CD40-mouse BAFFR
constructs described below were maintained in B cell medium con-
taining RPMI 1640 (Life Technology, Grand Island, NY, USA) with
10µM 2-βmercaptoethanol (Sigma Aldrich, St. Louis, MO, USA),
10% heat-inactivated FCS (Atlanta Biologicals, Atlanta, GA, USA),
2 mM l-Glutamine (Life Technologies), 100 U/ml of Penicillin
Streptomycin antibiotics (Life Technologies) (BCM10). Medium
additionally contained 400µg/ml of G418 disulfate (Research
Products International, Mount Prospect, IL, USA) for subclones
expressing transfected hCD40-BAFFR constructs, and both G418
and 200µg/ml of hygromycin (Life Technologies) for subclones
expressing FLAG-tagged TRAF3 or the LP1 mutant TRAF3.
DNA CONSTRUCTS AND TRANSFECTIONS
Plasmids encoding a mutant BAFFR from the A/WySnJ mouse
and a mouse BAFFR lacking the C-terminal eight amino acids
(∆C) were kindly provided by Drs. Colleen Hayes and Christo-
pher Mayne. These plasmids were used as a source of BAFFR
to produce cDNA encoding a chimeric molecule consisting of
the extracellular portion of human CD40 and the transmem-
brane and intracellular portions of mouse Wt BAFFR, the BAFFR
mutant of the A/WySnJ mouse, or mouse BAFFR lacking the C-
terminal 8 amino acids (∆C). These chimeric constructs were
subcloned into the mammalian expression vector pRSV5.neo for
stable expression in CH12.LX or M12.4.1 cells (33). cDNAs encod-
ing FLAG-tagged human Wt TRAF3, or the truncated TRAF3
mutant identified in the human MM cell line LP1 (14) were sub-
cloned into a variant of the pRSV5.neo plasmid with a sequence
containing the binding element of the repressor of the bacterial
Lac operon in the promoter, as previously described (33). This
allows Isopropyl β-d-1-thiogalactopyranoside (IPTG)-inducible,
stable TRAF3 expression in a CH12.TRAF3−/− cell line that stably
expresses the Lac repressor (32, 33). There is thus no endogenous
TRAF3 in cells expressing Wt or LP1 TRAF3 in these studies.
ANTIBODIES AND REAGENTS
Isopropyl β-d-1-thiogalactopyranoside was purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Rabbit anti-phospho-
jun kinase (JNK) Ab, rabbit anti-phospho-p38 Ab, rabbit anti-
pIκBαAb, rabbit anti-total IκBαAb, rabbit anti-NIK Ab, and rabbit
anti-p100/p52 Ab were purchased from Cell Signaling Technol-
ogy (Danvers, MA, USA). Rabbit anti-TRAF2 Ab was purchased
from Medical and Biological Laboratories (Woburn, MA, USA).
Anti-FLAG M2 Ab for immunoprecipitation, anti-FLAG M2-HRP
Ab for immunoblotting, and mouse anti β-actin Ab were pur-
chased from Sigma. Rabbit anti-JNK Ab, mouse anti-YY1 (H-10)
Ab, and rabbit anti-mouse CD40 (M-20) were purchased from
Santa Cruz Biotechnology (Dallas, TX, USA). Production of Hi
Five (HiV) strain insect cells infected with Wt baculovirus or bac-
ulovirus encoding human CD154 or mouse CD154 is described in
(34). Rat anti-mouse CD40 mAbs (1C10 and 4F11) were produced
in our laboratory from their respective hybridomas as described
(32), kindly provided by Dr. Frances Lund (University of Alabama,
Birmingham, AL, USA). The isotype control rat total IgG Ab
was purchased from Southern Biotech (Birmingham, AL, USA)
and mouse IgG1 control Ab from eBioscience (San Diego, CA,
USA). Goat anti-BAFFR Ab for immunoprecipitation was pur-
chased from R&D Systems (Minneapolis, MN, USA), and rabbit
anti-BAFFR Ab for immunoblotting was purchased from Abcam
(Cambridge, MA, USA). HRP-conjugated goat anti-mouse IgG
and goat anti-rabbit IgG secondary Abs were purchased from
Jackson ImmunoResearch Laboratories (West Grove, PA, USA).
CELL ISOLATION AND ASSAYS TO MEASURE RECEPTOR SIGNALING
AND TRAF3 DEGRADATION
Resting splenic B cells were obtained as previously described (9).
Briefly, high density splenic B cells were isolated by centrifugation
through a Percoll density gradient (GE Life Sciences, Pittsburg,
PA, USA) followed by anti-CD43 Ab-mediated negative selection,
using a magnetic bead kit (Miltenyi Biotec, Auburn, CA, USA),
according to the manufacturer’s protocol. 5× 106 splenic B cells
or 2× 106 CH12.LX or M12.4.1 cells were stimulated as indi-
cated in the Figure legends. After stimulation, cells were lysed and
cytosolic and nuclear extracts were prepared as described in Xie
et al. (35) to detect NF-κB2 activation via nuclear translocation
of p52. For proximal signaling assays and TRAF3 degradation
assays, 1–2× 106 cells were stimulated for indicated times at 37°C.
After stimulation, cells were lysed in 100µl 2× SDS-PAGE load-
ing buffer (1% SDS, 2% β-mercaptoethanol, 62.5 mM Tris, pH
6.8). Lysates were sonicated using a Branson Sonifier 250 (VWR
International, Radnor, PA, USA) with 10 pulses at 90% duty cycle,
output 1.5. Samples were boiled for 10 min at 95°C prior to gel
loading.
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IMMUNOPRECIPITATION
CH12.TRAF3−/− cells expressing LacR and stably transfected
with inducible FLAG-tagged Wt or LP1 mutant TRAF3 were
cultured with BCM10 containing 100µM IPTG overnight to
induce TRAF3 expression. 2× 107 cells were resuspended in 1 ml
BCM10 and stimulated with 10µg/ml of hamster anti-mouse
CD40 mAb (HM40.3, eBioscience) or 500 ng/ml of recombinant
BAFF (Peprotech, Rocky Hill, NJ, USA) for the indicated times.
Cells were pelleted and lysed in lysis buffer (0.5% Triton X, 40 mM
Tris, 100 mM NaCl, 1 mM MgCl2, 1 mM CaCl2) containing com-
plete protease inhibitor cocktail (Roche, Germany), 0.05 mg of
DNAse I (Roche), and 2 mM Na3VO4. Whole cell lyses were incu-
bated with mouse anti-FLAG Ab (Sigma) or control IgG1 Ab
overnight at 4°C with constant agitation. The immune complex
was precipitated with Dyna Protein G beads (Life Technologies),
washed and resuspended in SDS-PAGE loading buffer, and heated
to 95°C for 10 min.
IMMUNOPRECIPITATION FROM DETERGENT-INSOLUBLE PLASMA
MEMBRANE FRACTIONS
3× 107 CH12.LX cells were stimulated at 37°C with 500 ng/ml
recombinant BAFF (Peprotech) or 3× 106 HiV insect cells infected
with Wt baculovirus, or baculovirus expressing mouse CD154
(34). These insect cells, which grow at 25°C, die and serve as a
source of CD154-expressing membranes at 37°C. Cells were lysed
using buffer containing 1% Brij58 (Thermo Scientific, Rockford,
IL, USA), 150 mM NaCl, 20 mM Tris, 50 mM β-glycerophosphate,
1 mM MgCl2, 1 mM CaCl2, protease inhibitor cocktail, and 2 mM
Na3VO4. The Brij58-insoluble cell fractions were separated by
centrifugation at 14,000× g for 30 min at 4°C and solubilized
using 1% Triton X-100 and 0.1% SDS-containing buffer. This sol-
ubilized cholesterol-rich membrane fraction (22) was subjected
to immunoprecipitation using rat anti-mouse CD40 mAbs (an
equal mixture of the clones 1C10 and 4F11) (36), goat poly-
clonal anti-BAFFR Ab, or appropriate isotype control antibodies.
To immunoprecipitate the receptor signaling complex, Protein G
Dyna beads, pre-incubated with goat anti-rat Ab (Jackson) for
30 min at room temperature, or uncoupled beads were incubated
with solubilized membrane fractions for 2 h at 4°C with constant
agitation. After washing, the immunoprecipitate was deglycosy-
lated using PNGaseF (NEB) and boiled in SDS-PAGE loading
buffer.
IMMUNOPRECIPITATION OF HCD40-BAFFR CHIMERIC MOLECULES
3× 107 cells CH12.LX cells that stably express hCD40-BAFFR
(Wt), hCD40-A/WySnJ (A/WySnJ), hCD40-∆C, or hCD40-
BAFFR chimeric molecules with a mutated TRAF3 binding site
(AVAAA) were stimulated with Protein G Dyna Beads (Life Tech-
nologies) conjugated with agonistic mouse anti-hCD40 mAb or
isotype control Ab for the indicated time points at 37°C. Abs
were crosslinked to the beads using DSS crosslinker (Thermo Sci-
entific) according to the manufacturer’s recommended protocol.
Immunoprecipitation of hCD40-BAFFR chimeric molecules was
performed as previously described (37).
WESTERN BLOTS
Proteins were resolved on SDS-PAGE gels and transferred to PVDF
membranes (Millipore, Billerica, MA, USA). Membranes were
blocked in 5% milk in TBST (120 mM NaCl, 0.08% Tween 20, and
40 mM Tris) for 1 h at room temperature, and incubated overnight
at 4°C in primary Ab. Blots were washed in TBST, incubated with
secondary Abs for 2 h at room temperature and developed using
Supersignal West Pico (Thermo Scientific). Western blot chemi-
luminescence was read with an LAS-4000 low-light camera and
analyzed with Multi Gage software (Fujifilm Life Science, Edison,
NJ, USA).
STATISTICAL ANALYSIS
p-Values were generated by Student’s t -test (unpaired, two-tailed,
at 95% confidence interval).
RESULTS
RECEPTOR-INDUCED DEGRADATION OF Wt VS. LP1 TRAF3
We and others previously reported that B cell-specific loss of the
traf3 gene enhances the survival of B cells independent of cell
proliferation (9, 10). We also demonstrated that this enhanced B
cell-specific survival renders B cells independent of the soluble
factor BAFF, and results in constitutive activation of the non-
canonical NF-κB2 pathway (9). At the same time, several groups
reported that loss-of-function mutations in the traf3 gene are asso-
ciated with human MM and enhanced NF-κB2 activity (13, 14).
These studies identified various forms of TRAF3 mutations, from
point mutations leading to single amino acid substitutions to large
truncations. These mutations of traf3 are highly correlated with
frequent chromosomal translocations of chromosome 14, com-
monly seen in MM (13, 14). Among these is a TRAF3 mutation
identified in the human MM LP1 cell line. The LP1 TRAF3 mis-
sense mutation results in production of a truncated TRAF3 lacking
the TRAF-N and TRAF-C domains (Figure 1A), which we predict
would fail to associate with TRAF2 (19) and thus not undergo
receptor-mediated degradation.
To test our prediction that the LP1 TRAF3 mutant fails
to undergo receptor-mediated degradation, we established
CH12.TRAF3−/− subclones with stable, IPTG-inducible expres-
sion of FLAG-tagged Wt or LP1 TRAF3. Cells were stimulated via
CD40 or BAFFR, known strong activators of TRAF2-dependent
TRAF3 degradation (22, 24, 25). Based on the results shown in
Figures 1B,C, LP1 was only minimally degraded after stimulation
with CD40 or BAFFR, compared to Wt TRAF3.
RECEPTOR-INDUCED NF-κB2 AND JNK ACTIVATION IN
LP1-EXPRESSING CELLS
A widely held paradigm is that TRAF3 degradation induced by
CD40 or BAFFR ligation allows NIK stabilization, which then acti-
vates the NF-κB2 pathway (20, 26, 27). This paradigm predicts that
TRAF3−/− cells expressing LP1 would fail to undergo receptor-
induced NF-κB2 activation, as LP1 is not able to undergo receptor-
induced degradation. To investigate whether LP1 is inducing
NF-κB2 activation independent of receptor-induced degradation,
we provided CD40 or BAFF stimuli to CH12.TRAF3−/− B cells
induced to express either Wt or LP1 TRAF3. Consistent with
TRAF3’s proposed role in NF-κB2 activation, induction of Wt
TRAF3 expression reduced nuclear p52 from its elevated levels
in TRAF3−/− B cells. Because the LP1 TRAF3 mutant is a loss-
of-function mutation, we predicted that LP1 TRAF3-expressing
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FIGURE 1 | Dissociation between CD40 and BAFF-mediated NF-κB2
activation andTRAF3 degradation. (A) Schematic presentation of Wt and
LP1 mutant TRAF3. (B,C) CH12.TRAF3−/− cells stably transfected for inducible
expression of FLAG-tagged Wt or LP1 mutant TRAF3 were treated overnight
with IPTG to induce TRAF3 expression, as described in Section “Materials
and Methods.” Induced cells were either untreated (M) or treated with
isotype control Ab (C) or stimulated with 5µg/ml of anti-CD40 mAb (B) or
200 ng/ml of recombinant BAFF (C) for the indicated times at 37°C. Whole
cell lysates were resolved by SDS-PAGE and Western blots of gel probed with
anti-FLAG Ab to assess relative cellular levels of Wt and LP1 TRAF3. Graphs
depict mean values±SEM of TRAF3 band intensities, normalized to actin,
from immunoblots of three experiments. **Statistically significant differences
between Wt and LP1TRAF3, analyzed as in Section “Materials and Methods.”
Numbers on the graph indicate the highest p values for individual time points.
B cells will have constitutive nuclear p52 and there will be no
further activation of the NF-κB2 pathway upon stimulation. Inter-
estingly, however, induction of LP1 expression in TRAF3−/− B cells
also reduced nuclear p52 levels (Figures 2A,B). Induction of LP1
expression reduced basal nuclear p52 levels in TRAF3−/− B cells.
However, p52 levels remained ~twofold higher in LP1 compared
to Wt TRAF3-expressing cells (Figures 2A,B), which is consistent
with previous observations in myeloma cells and fibroblasts that
the presence of LP1 TRAF3 mutant led to higher p52 levels (8, 14).
Surprisingly, unlike TRAF3-deficient B cells, which further acti-
vate NF-κB2 in response to CD40 but not BAFFR stimulation (9),
LP1-expressing B cells responded to both CD40 and BAFF stimu-
lation with further nuclear p52 increases (Figures 2A,B). These
data suggested that the TRAF3 mutant LP1 partially restrains
NF-κB2 activation, and upon stimulation activates the NF-κB2
pathway independent of receptor-mediated LP1 degradation. Col-
lectively, published studies and results presented here lead us
to propose that induction of NF-κB2 activation in B cells does
not solely depend on the absence of TRAF3, whether TRAF3
reduction is caused by receptor-induced degradation, mutation,
or gene-targeted deletion.
LP1 expression also resulted in enhanced c-JNK activation
following BAFF stimulation (Figure 2D), and sustained and sig-
nificantly enhanced JNK activation in response to CD40 signals
(Figure 2C). In contrast, neither phosphorylation of the mitogen-
activated kinase (MAPK) p38 nor activation of classical NF-κB1
was impacted by the LP1 mutation compared to Wt TRAF3
(Figure 3). These data indicate that the C-terminal domains
of TRAF3 are important for restraining activation of the JNK
pathway. Consistent with our prior report that complete loss of
TRAF3 does not impact CD40-mediated NF-κB1 activation (9),
LP1 expression did not result in enhanced NF-κB1 or p38 acti-
vation in response to CD40 or BAFFR signals. Canonical NF-κB1
activation was unaffected by LP1 TRAF3 expression, indicating
that increased nuclear p52 levels in LP1-expressing cells were not
due to NF-κB1-induced enhanced p100 expression.
ASSOCIATION OF TRAF3 WITH KEY SIGNALING COMPONENTS IN
NF-κB2 ACTIVATION
TRAF3 is typically recruited to the cytoplasmic domains of CD40
and BAFFR, together with TRAFs, to mediate downstream signal-
ing and biological functions (22, 23, 38). Recruitment to receptor
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FIGURE 2 | Impact ofTRAF3 on CD40 and BAFFR-mediated NF-κB2 and
JNK activation. CH12.TRAF3−/− cells were induced to express Wt or
mutant LP1 TRAF3 as in Figure 1. (A,B) Cells were untreated (M) or treated
with isotype control Ab (C) or stimulated with 5µg/ml of anti-mouse CD40
mAb (HM40.3) (A) or 200 ng/ml of recombinant BAFF (B) for the indicated
times at 37°C. Uninduced cells were also included as control (Un). Cytosolic
and nuclear extracts of cell lysates were prepared and immunoblotted for
the NF-κB2 precursor protein p100 and its cleavage product p52, with
probes for actin and YY1 serving as loading controls for cytoplasmic and
nuclear protein levels respectively. YY1 levels were used to normalize
nuclear p52 values shown quantitatively in graphs. Representative blots
from cells stimulated via CD40 (A) or BAFFR (B) are shown. Graphs in
(A,B) show mean values±SEM of fold increases in normalized band
intensities of nuclear p52 from five (CD40) or four (BAFF) independent
experiments. Values from LP1-expressing cells were divided by values from
Wt TRAF3-expressing unstimulated cells. (C,D) 1×106 cells were
stimulated with 10µg/ml of anti-mouse CD40 mAb or 500 ng/ml of BAFF for
the indicated times. Whole cell lysates were prepared, and Western blots
probed for phosphorylated JNK (pJNK), total JNK (JNK), and actin.
Representative blots are presented. The corresponding graphs represent
mean values for band intensities of pJNK divided by total JNK±SEM from
two (BAFF) or three (CD40) independent experiments.
cytoplasmic domains and association with TRAF2 and/or cIAP1/2
are thought to be required for K48-mediated ubiquitination,
followed by proteasomal degradation of TRAF3 after receptor
engagement (24, 25, 39, 40). To investigate the reason for the lack of
receptor-mediated LP1 degradation, we assessed whether LP1 can
associate with TRAF2. CH12.TRAF3−/− B cells induced to express
Wt or LP1 TRAF3 were stimulated through CD40, and Wt or
LP1 TRAF3 was immunoprecipitated from cell lysates. Consistent
with a previous report (19), the C-terminal TRAF-N and TRAF-
C domains of TRAF3 were required for TRAF3 to associate with
TRAF2, with or without CD40 stimulation (Figure 4A). Similar
results were obtained with BAFF stimulation (data not shown).
To assess whether LP1 associated with either CD40 or BAFFR
after stimulation, we isolated the lipid-raft enriched detergent-
insoluble plasma membrane fractions of cells as described in
Section “Materials and Methods,” and immunoprecipitated the
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FIGURE 3 | Impact ofTRAF3 on CD40 and BAFFR-mediated NF-κB1 and
p38 MAP kinase activation. CH12.TRAF3−/− cells were induced to express
Wt or mutant LP1 TRAF3 as in Figure 1. Cells were stimulated as described
in Figures 2C,D via CD40 (A) or BAFFR (B), and immunoblots of whole cell
lysate samples were probed for phosphorylated IκBα (p IκBα), total IκBα,
phospho p38 (p-p38), and actin (used as a control for p-p38 because
antibodies to total p38 also recognize the phosphorylated form).
Representative blots from three independent experiments are shown.
receptor signaling complex. Figures 4B,C reveal that LP1 was not
part of the CD40 or BAFFR signaling complexes, but Wt TRAF3
associated with the receptors upon stimulation. These data sug-
gest that the observed lack of receptor-induced LP1 degradation
reflects a requirement for recruitment of TRAF3 to the receptor
cytoplasmic domains and association with TRAF2, to initiate the
degradation process.
Strikingly, despite lack of receptor-mediated degradation of
LP1 TRAF3, LP1-expressing B cells were capable of inducing
NF-κB2 activation above the already high basal levels following
receptor stimulation. To address this discrepancy with the prevail-
ing paradigm, we investigated whether LP1 associates with NIK, a
MAP kinase implicated as key to NF-κB2 activation (21). A pre-
vious report showed that TRAF3 physically interacts with NIK
when both molecules are overexpressed in transformed epithelial
cells, and this interaction requires the C-terminal residues from
424 to 543 of TRAF3 (20). The interaction between TRAF3 and
NIK is proposed to allow the TRAF2 E3 ubiquitin ligase activ-
ity to constantly ubiquitinate NIK for proteosomal degradation
(20, 26, 27). Hence, although LP1 was not degraded after receptor
stimulation (Figure 1), if NIK fails to associate with LP1, this
could stabilize NIK in LP1-expressing cells, ultimately leading
to enhanced NF-κB2 activation. However, immunoprecipitated
LP1 TRAF3 from unstimulated or BAFF-activated B cells dis-
played 10–16 fold increased association with NIK, compared to
Wt TRAF3 (Figure 5). Notably, there was no drastic difference
in total NIK accumulation in LP1 vs. Wt TRAF3-expressing B
cells. It is important to note that the function of TRAF3 is highly
context-dependent; TRAF3 plays very different roles with regards
to distinct receptors and cell types [reviewed in Ref. (2)]. Thus,
the discrepancy between the present findings and previous con-
clusions based upon experiments performed in epithelial cell lines
(20) are likely due to these contextual differences. Collectively, the
present results suggest that when tumor-derived mutant TRAF3
becomes resistant to receptor-mediated degradation, stabiliza-
tion of cellular NIK levels is controlled by TRAF3 degradation-
independent mechanisms to regulate NF-κB2 activation in B
cells.
DEFECTIVE NF-κB2 ACTIVATION VIA THE MUTANT BAFFR OF A/wysnj B
CELLS
B cell activating factor receptor provides an important B cell sur-
vival signal, thought to require activation of the non-canonical
NF-κB2 pathway (5). As a complementary experimental model
to further examine the importance of receptor-mediated TRAF3
degradation for NF-κB2 activation in B cells, we isolated B cells
from the A/WySnJ mouse. This mouse contains a spontaneous
mutation in the Baffr gene called Bcmd1 (B cell maturation defect-
1) that leads to defects in survival and maturation of peripheral
B cells (41). Bcmd1 encodes a protein that shares ≥95% sequence
homology with Wt BAFFR. Notably, the TRAF3 binding motif
PVPAT remains intact in this mutant BAFFR (Figure 6A) (42).
However, the last eight amino acids of Wt BAFFR are replaced
by a 22-amino acid peptide sequence resulting from a proviral
Intracisternal A-particle (IAP) retro-transposon insertion event
(41). Although A/WySnJ mice have considerably reduced periph-
eral B cell numbers due to reduced B cell survival, the expression
of tg Bcl2 restores the peripheral B cell compartment to near-
normal levels (29). We thus utilized A/WySnJ-Bcl2 Tg mice for
these experiments (designated A/WySnJ in Figures for simplicity).
When we stimulated their splenic B cells with BAFF, the NF-κB2
pathway showed markedly defective activation compared to con-
trol mice of the parent strain (A/J) expressing tg Bcl2 (Figure 6B).
Consistent with the concept that BAFF binding to BAFFR pref-
erentially activates the NF-κB2 pathway (43), BAFFR−/− B cells
were not able to active NF-κB2 in response to BAFF stimulation
(Figure 6B). In Figure 6B, we also noted that A/WySnJ BAFFR sig-
naling induced TRAF3 degradation to a similar extent as did Wt
BAFFR. We also examined the endogenous NIK protein levels in
B cells of Wt and BAFFR mutant mice, and found that there were
no differences in cellular NIK levels in A/WySnJ B cells as com-
pared to Wt B cells (Figure 6C). These data suggest that TRAF3
degradation, leading to NIK stabilization, is not sufficient in itself
to activate the non-canonical NF-κB2 pathway.
Because BAFF binds to three receptors expressed on B cells,
BAFFR (44), BCMA (B cell maturation antigen) (45), and TACI
(transmembrane activator and calcium modulator and cyclophilin
ligand) (46), it is important to verify that the defective BAFF
response of splenic B cells from the A/WysnJ mouse is due to
its mutant BAFFR. We thus generated CH12.LX and M12.4.1
mouse B cell lines stably expressing chimeric receptors, con-
taining the human (h)CD40 extracellular and transmembrane
domains fused to the cytoplasmic domain of Wt BAFFR (Wt),
the A/WySnJ mutant BAFFR, or BAFFR that lacks the last eight
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FIGURE 4 | Impaired association of LP1TRAF3 withTRAF2, CD40, and
BAFFR. (A) CH12.TRAF3−/− cells induced to express FLAG-tagged Wt or LP1
as in previous Figures were untreated or stimulated with 10µg/ml of
anti-CD40 mAb. Whole cell lysates were prepared as described in Section
“Materials and Methods” and immunoprecipitated with anti-FLAG Ab and
Western blots were probed for TRAF2 and FLAG. The bar graph presents
quantification of relative amounts of TRAF3-associated TRAF2 from three
independent experiments. **p= 0.001; ***p=0.0005; n.d.=none detected.
(B) Cells were stimulated with HiV insect cells infected with Wt baculovirus,
or HiV cells expressing baculovirus-encoded mouse CD154.
Detergent-insoluble plasma membrane fractions were prepared from cell
lysates and subjected to immunoprecipitation with anti-mCD40 Ab as in
Section “Materials and Methods.” Western blots were probed for FLAG and
CD40. Graph represents quantification of mean values of relative amounts of
TRAF3 associating with membrane CD40 from two different experiments.
*p=0.03; **p=0.005. (C) Cells were untreated or cultured with 500 ng/ml
of BAFF as indicated. Detergent-insoluble membrane fractions were isolated
as above and anti-BAFFR Ab were used to immunoprecipitate the receptor
signaling complex. Western blots of immunoprecipitates were probed for
FLAG and BAFFR. The bar graph shows quantification of mean relative
amounts of TRAF3 associated with BAFFR, from two different experiments.
*p=0.03; **p=0.003.
amino acids of the cytoplasmic domain (∆C) (Figure 6D). The
chimeric receptors allowed us to be certain that we were examin-
ing consequences of BAFFR signaling in these B cells. B cells were
stimulated with HiV insect cells expressing hCD154, and NF-κB2
activation was analyzed. Stimulation with anti-mouse (m)CD40
agonistic Ab served as an internal control, showing that there was
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FIGURE 5 | Enhanced association of LP1TRAF3 with NIK.
CH12.TRAF3−/− cells expressing FLAG-tagged Wt or LP1 TRAF3 were
untreated or stimulated with 500 ng/ml of BAFF. Whole cell lysates were
prepared and immunoprecipitated with anti-FLAG Ab. Western blots of
immunoprecipitates were probed for NIK and FLAG. Both short and long
exposures of the blot are shown due to differences in NIK association
between Wt and LP1 TRAF3. Data shown are representative of two similar
experiments.
no global defect in CD40 signaling of cells expressing various
chimeric molecules. Consistent with results from primary splenic
B cells from A/WySnJ or control mice, B cells expressing hCD40-
A/WySnJ BAFFR displayed defective NF-κB2 activation compared
to hCD40-Wt BAFFR (Figure 6E). This result indicates that the
signaling defect observed in splenic B cells is due to the dysfunc-
tional BAFFR. Impaired activation of NF-κB2 was also observed
with hCD40-∆C BAFFR, indicating that the last eight amino acids
of BAFFR are necessary for NF-κB2 activation, although they have
been shown to be dispensable for B cell survival (29). This reveals
the interesting information that pathways alternative to NF-κB2
can mediate BAFFR-induced B cell survival.
TRAF3 DEGRADATION MEDIATED BY MUTANT BAFFRS
To explore whether TRAF3 degradation status correlates with the
impaired activation of NF-κB2 in cells expressing mutants of
BAFFR, we stimulated B cell transfectants shown in Figure 6C
through hCD40-BAFFR to induce BAFFR-mediated TRAF3
degradation (Figure 7A). TRAF3 was degraded similarly, regard-
less of which BAFFR cytoplasmic domain was expressed. This
result reveals that TRAF3 degradation is not sufficient to
induce BAFFR-mediated NF-κB2 activation. Results presented
in Figures 6B and 7A led us to predict that TRAF recruitment
to the A/WySnJ BAFFR cytoplasmic tail would be compara-
ble to TRAF recruitment to Wt BAFFR. Indeed, cells express-
ing hCD40-A/WySnJ chimeric molecules not only were able
to recruit both TRAF2 and 3 to the BAFFR, this mutant
BAFFR showed enhanced TRAF recruitment compared to Wt
BAFFR (Figure 7B). Consistent with previous studies, when
the TRAF3 binding site (PVPAT) on BAFFR was disrupted
(AVAAA), there was no recruitment of TRAFs to the recep-
tor’s cytoplasmic domain (Figure 7B). These results show that
the defective BAFF-stimulated NF-κB2 activation in A/WySnJ B
cells is not due to a failure to induce TRAF3 recruitment or
degradation.
Taken together, results from experiments presented in this
study indicate that receptor-mediated TRAF3 degradation is not
sufficient to induce NF-κB2 activation in B cells and TRAF3
degradation-independent mechanisms can also regulate the NF-
κB2 pathway.
DISCUSSION
Functions of TRAF molecules vary both between cell types, and
between individual types of receptors even within the same cell.
This is particularly true for TRAF3 (2). There are many disad-
vantages of using the experimental model of transient overexpres-
sion in transformed cell lines, usually epithelial or fibroblast, to
understand how endogenous signaling pathways work in specific
hematopoietic cell types [reviewed in Ref. (47)]. Unfortunately,
a great deal of the experimental investigation of TRAF3 func-
tions to date has relied upon overexpression models. Largely based
upon such models, it was concluded that receptor-induced TRAF3
degradation leading to NIK stabilization is a crucial requirement
for downstream activation of the non-canonical NF-κB2 pathway
(20, 26, 27).
We wished to further explore this model in B lymphocytes, as
our previous findings, and those of others, indicate that TRAF3
plays uniquely important roles in regulation of this cell type. Our
results presented here using complementary experimental sys-
tems of primary B cells and B cell lines, demonstrate that TRAF3
degradation is not sufficient for downstream NF-κB2 activation.
The results from our study further emphasize the importance
of studying TRAF functions in a cell type and receptor-specific
manner. In this study, we also demonstrated TRAF-N and TRAF-
C domains are required for recruitment of TRAF3 to CD40
and BAFFR, and that association with the TRAF2 complex is
necessary for receptor-mediated TRAF3 degradation (Figures 1
and 4). However, the lack of degradation of the MM-derived
TRAF3 mutant LP1 did not prevent activation of downstream
signaling pathways; in fact, LP1-expressing B cells showed sim-
ilar ability to undergo receptor-induced NF-κB2 activation, and
enhanced JNK activation. In contrast to a previous study per-
formed in non-hematopoietic cells (20), we found that TRAF3
association with the NF-κB2-activating kinase NIK in B cells does
not require the TRAF-N and TRAF-C domains. Although lacking
these domains, the LP1 mutant TRAF3 molecule actually bound
substantially more NIK than Wt TRAF3. While the explanation
for this enhanced binding is currently unknown, it is possible that
one or more additional protein–protein interactions are involved.
A slight increase in total NIK protein in LP1-expressing cells also
suggested that NIK stabilization can be controlled by additional
mechanisms. IKKα phosphorylation of NIK also destabilizes NIK
(48). Additionally, TBK1 stabilizes NIK protein levels independent
of TRAF3 degradation, while in contrast the protein OTUD7B reg-
ulates NIK protein levels through TRAF3 degradation in B cells
(49, 50). Unlike TRAF3-deficient B cells, LP1 TRAF3-expressing
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FIGURE 6 | Impaired NF-κB2 activation induced by mutant BAFFRs.
(A) Comparison of the C-terminal signaling domain amino acid sequences of
Wt and A/WySnJ BAFFRs. Bold and underlined sequences indicate the TRAF3
binding motif, numbers above the sequences indicate the position of the
amino acids. (B) Equal numbers of resting splenic B cells isolated from Wt
(+/+), A/WySnJ, and BAFFR−/− (−/−) mice were stimulated with 100 ng/ml of
BAFF for 26 h. Cytosolic and nuclear fractions were prepared and subjected to
SDS-PAGE as in Section “Materials and Methods.” Western blots of samples
were probed for p100/p52, TRAF3, actin, and YY1, as in Figure 1. Numbers on
the TRAF3 blot indicate mean values of the proportion of remaining TRAF3
relative to unstimulated controls of each genotype, from two independent
experiments. Numbers on the blot of nuclear extracts represent averages of
the fold increase over unstimulated control within each strain of mouse, from
two independent experiments. (C) Equal numbers of splenic B cells isolated
from Wt or A/WySnJ mice were stimulated with 200 ng/ml of BAFF for the
indicated times. Whole cell lysates were immunoblotted for NIK and actin.
Representative blots from two independent experiments are shown.
(D) C-terminal amino acid sequences encoded by chimeric constructs of
hCD40-BAFFR, used to stably transfect CH12.LX cells as described in Section
“Materials and Methods.” (E) CH12.LX B cell subclones stably expressing
various hCD40-BAFFR chimeras were treated with medium only (M), control
HiV insect cells (C), or HiV insect cells expressing hCD154 for the indicated
times. Anti-mCD40 agonistic mAb (1C10) treatment for 9 h served as an
internal control for each subclone (91C10). Nuclear extracts were prepared and
Western blots probed for p100/p52, and YY1. Representative blots of three
similar experiments are shown. The corresponding graph represents mean
band intensity values of treated/control samples±SEM of three independent
experiments.
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FIGURE 7 | Dissociation between relativeTRAF3 degradation and
NF-κB2 activation mediated byWt vs. mutant BAFFRs. (A) Subclones
of the M12.4.1 B cell line stably transfected with various forms of
hCD40-BAFFR chimeras shown in Figure 6C were untreated (M), or
treated with HiV insect cells (C), or HiV insect cells expressing hCD154 for
the indicated times, or anti-mCD40 agonistic Ab 1C10 for 8 h (81C10). Whole
cell lysates were prepared and subjected to SDS-PAGE as in Section
“Materials and Methods.” Representative immunoblots of samples,
probed for TRAF3 and GAPDH are presented. The graph depicts relative
amounts of TRAF3, normalized to GAPDH. Values presented are
mean±SEM of data combined from three independent experiments.
(B) CH12.LX B cells subclones as in Figure 6D and CH12.LX B cells that
expressed hCD40-BAFFR with disrupted TRAF3 binding sites (AVAAA)
were stimulated with anti-hCD40 mAb or isotype control (Iso) coated
beads and immunoprecipitated as mentioned in Section “Materials and
Methods.” The bead bound protein complexes were separated on
SDS-PAGE and immunoblotted for TRAF2 and TRAF3. Representative blots
from three independent experiments were shown. Bar graph represents
relative levels of TRAF2 and TRAF3 normalized to hCD40-BAFFR chimera
molecules.
B cells responded to both BAFF and CD40 stimulation with fur-
ther increases in nuclear p52 levels. The current proposed model
is that TRAF3 association with the TRAF2-cIAP complex pre-
vents activation of the NF-κB2 pathway. Results presented here
indicate that the mechanism by which TRAF3 regulates NF-κB2
activation is more complex than this. The degradation-resistant
LP1 mutant TRAF3, without complexing with TRAF2-cIAP, can
still regulate NF-κB2 activation. Our results also showed that the
amino terminal RING and Zinc finger domains of TRAF3 are also
quite important for TRAF3 to restrain NF-κB2 activation, in accor-
dance with a published study (8). Taken together, the published
and present data demonstrate that there are multiple mechanisms
by which TRAF3 regulates the NF-κB2 pathway in B cells, both
dependent upon, and independent of receptor-mediated TRAF3
degradation.
B cell activating factor receptor-mediated activation of signal-
ing pathways is important for B cell homeostasis and survival,
as exemplified by the deficiencies in mature B cell numbers and
function observed in BAFF−/− and BAFFR−/− mice, as well as the
spontaneous BAFFR mutant-expressing mouse, A/WySnJ (5). The
NF-κB2 pathway is robustly activated by BAFFR, and is thought
to play a major role in BAFFR-mediated B cell survival signals
(21). Thus, the previously presented paradigm of NF-κB2 activa-
tion predicts that loss-of-function mutants of BAFFR would show
reduced ability to induce TRAF3 degradation in B cells. Consis-
tent with previous reports (28, 51), we observed impaired BAFF-
mediated NF-κB2 activation in B cells isolated from A/WySnJ and
BAFFR−/− mice, as well as with B cell lines expressing mutant
hCD40-BAFFR chimeric receptors. We further demonstrated that
the last eight amino acids of the BAFFR cytoplasmic domain are
required for NF-κB2 activation in B cells. This is particularly inter-
esting, because Mayne and Hayes reported that these residues are
NOT required for BAFFR-mediated B cell survival (29). Together
with the present results, this indicates that NF-κB2 activation is
not the only important pro-survival pathway induced by BAFFR
signaling.
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Several studies have concluded that receptor-induced TRAF3
degradation is sufficient to activate the NF-κB2 pathway (20, 26,
27). Because the A/WySnJ BAFFR retains the TRAF3 binding motif
PVPAT, we compared BAFFR-inducedTRAF3 degradation using B
cells expressing different forms of BAFFR. Again in contrast to the
current paradigm, we found that signaling through the A/WySnJ or
∆C BAFFRs induced TRAF3 degradation to levels similar to Wt
BAFFR, leading to the conclusion that receptor-induced TRAF3
degradation is not sufficient to drive NF-κB2 activation. Addi-
tionally, the A/WySnJ BAFFR recruits more TRAF2 and 3 to its
cytoplasmic tail, so it is possible that the mutant BAFFR is recruit-
ing important additional, unidentified signaling molecules that
regulate NF-κB2 activation. We also found that the last eight amino
acids of the C terminus of BAFFR were not required for either
receptor-mediated TRAF3 degradation or TRAF recruitment to
the receptor, but the impact of this region upon recruitment of
other unidentified factors are not yet known.
In summary, our data demonstrate that the relationship
between TRAF3 degradation and activation of NF-κB2 in B cells
is neither simple nor linear. These findings support the need for
further investigation into both how NF-κB2 activation is regulated
in B cells, as well as how TRAF3 may regulate B cell survival via
mechanisms additional to NF-κB2 activation. The identification
of loss-of-function TRAF3 mutations in various types of human B
cell malignancies underlines the importance of reaching a clearer
and more detailed understanding of these relationships.
AUTHOR CONTRIBUTIONS
Wai W. Lin, Joanne M. Hildebrand, and Gail A. Bishop designed
research; Wai W. Lin and Joanne M. Hildebrand performed exper-
iments. Wai W. Lin, Joanne M. Hildebrand, and Gail A. Bishop
prepared the manuscript.
ACKNOWLEDGMENTS
The authors are grateful to Drs. Colleen Hayes and Christopher
Mayne for provision of some of the mouse strains used in this
study, as well as BAFF receptor constructs, as described in Section
“Materials and Methods.” We thank Dr. Ahmad Halwani for pro-
duction of the FLAG-tagged human TRAF3 and LP1 TRAF3
plasmids. We also thank Dr. Bruce Hostager for critical review of
the manuscript and helpful comments. This work was supported
by NIH grants AI028847 and AI049993 and a Research Career Sci-
entist award from the Department of Veterans Affairs to Gail A.
Bishop. This material is based upon work supported in part by
facilities and equipment provided by the Department of Veterans
Affairs, Veterans Health Administration, Office of Research and
Development. Joanne M. Hildebrand received support from an
Overseas Biomedical Postdoctoral Fellowship from the Australian
NHMRC (#541951).
REFERENCES
1. Hacker H, Tseng PH, Karin M. Expanding TRAF function: TRAF3 as a tri-faced
immune regulator. Nat Rev Immunol (2011) 11:457–68. doi:10.1038/nri2998
2. Hildebrand JM, Yi Z, Buchta CM, Poovassery J, Stunz LL, Bishop GA. Roles of
TRAF3 and TRAF5 in immune cell functions. Immunol Rev (2011) 244:55–74.
doi:10.1111/j.1600-065X.2011.01055.x
3. Xie P, Kraus ZJ, Stunz LL, Liu Y, Bishop GA. TRAF3 is required for T cell-
mediated immunity and TCR/CD28 signaling. J Immunol (2011) 186:143–55.
doi:10.4049/jimmunol.1000290
4. Bishop GA. The multifaceted roles of TRAFs in the regulation of B-cell function.
Nat Rev Immunol (2004) 4:775–86. doi:10.1038/nri1462
5. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol (2009)
9:491–502. doi:10.1038/nri2572
6. Sun SC. Non-canonical NF-κB signaling pathway. Cell Res (2011) 21:71–85.
doi:10.1038/cr.2010.177
7. He JQ, Zarnegar B, Oganesyan G, Saha SK, Yamazaki S, Doyle SE, et al. Rescue of
TRAF3-null mice by p100 NF-kappa B deficiency. J Exp Med (2006) 203:2413–8.
doi:10.1084/jem.20061166
8. He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G. Specificity of TRAF3 in its neg-
ative regulation of the non-canonical NF-kappa B pathway. J Biol Chem (2007)
282:3688–94. doi:10.1074/jbc.M610271200
9. Xie P, Stunz LL, Larison KD, Yang B, Bishop GA. TRAF3 is a critical regulator of
B cell homeostasis in secondary lymphoid organs. Immunity (2007) 27:253–67.
doi:10.1016/j.immuni.2007.07.012
10. Gardam S, Sierro F, Basten A, Mackay F, Brink R. TRAF2 and TRAF3 sig-
nal adapters act cooperatively to control the maturation and survival sig-
nals delivered to B cells by the BAFF receptor. Immunity (2008) 28:391–401.
doi:10.1016/j.immuni.2008.01.009
11. Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: impli-
cations for human disease. Oncogene (2006) 25:6831–43. doi:10.1038/sj.onc.
1209939
12. Jost PJ, Ruland J. Aberrant NF-κB signaling in lymphoma: mechanisms, conse-
quences, and therapeutic implications. Blood (2007) 109:2700–7.
13. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al.
Frequent engagement of the classical and alternative NF-κB pathways by diverse
genetic abnormalities in multiple myeloma. Cancer Cell (2007) 12:115–30.
doi:10.1016/j.ccr.2007.07.004
14. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous
mutations activate the non-canonical NF-κB pathway in multiple myeloma.
Cancer Cell (2007) 12:131–44. doi:10.1016/j.ccr.2007.07.003
15. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R,
et al. Identification of copy number abnormalities and inactivating muta-
tions in two negative regulators of nuclear factor-kappaB signaling path-
ways in Waldenstrom’s macroglobulinemia. Cancer Res (2009) 69:3579–88.
doi:10.1158/0008-5472.CAN-08-3701
16. Nagel I, Bug S, Tonnies H, Ammerpohl O, Richter J, Vater I, et al. Bial-
lelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial
del(14)(q24.1q32.33). Leukemia (2009) 23:2153–5. doi:10.1038/leu.2009.149
17. Poulain S, Braggio E, Roumier C, Aijjou R, Broucqsault N, Galiegue-Zouitina S,
et al. High-throughput genomic analysis in Waldenstrom’s macroglobulinemia.
Clin Lymphoma Myeloma Leuk (2011) 11:106–8. doi:10.3816/CLML.2011.n.021
18. Moore CR, Liu Y, Shao C, Covey LR, Morse HC III, Xie P. Specific deletion of
TRAF3 in B lymphocytes leads to B-lymphoma development in mice. Leukemia
(2012) 26:1122–7. doi:10.1038/leu.2011.309
19. He L, Grammer AC, Wu X, Lipsky PE. TRAF3 forms heterotrimers with TRAF2
and modulates its ability to mediate NF-κB activation. J Biol Chem (2004)
279:55855–65. doi:10.1074/jbc.M407284200
20. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-κB-inducing
kinase by TRAF3-induced degradation. J Biol Chem (2004) 279:26243–50.
doi:10.1074/jbc.M403286200
21. Sun SC. The non-canonical NF-κB pathway. Immunol Rev (2012) 246:125–40.
doi:10.1111/j.1600-065X.2011.01088.x
22. Hostager BS, Catlett IM, Bishop GA. Recruitment of CD40 and TRAF2 and
3 to membrane microdomains during CD40 signaling. J Biol Chem (2000)
275:15392–8. doi:10.1074/jbc.M909520199
23. Xu LG, Shu HB. TRAF3 is associated with BAFF-R and negatively regulates
BAFF-R-mediated NF-κB activation and IL-10 production. J Immunol (2002)
169:6883–9.
24. Brown KD, Hostager BS, Bishop GA. Differential signaling and TRAF degrada-
tion mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane
protein 1 (LMP1). J Exp Med (2001) 193:943–54. doi:10.1084/jem.193.8.943
25. Brown KD, Hostager BS, Bishop GA. Regulation of TRAF2 signaling by
self-induced degradation. J Biol Chem (2002) 277:19433–8. doi:10.1074/jbc.
M111522200
26. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, et al.
Non-redundant and complementary functions of TRAF2 and TRAF3 in a ubiq-
uitination cascade that activates NIK-dependent alternative NF-kappaB signal-
ing. Nat Immunol (2008) 9:1364–70. doi:10.1038/ni.1678
www.frontiersin.org December 2013 | Volume 4 | Article 477 | 11
Lin et al. TRAF3 degradation and NF-κB2 activation
27. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, et al.
Non-canonical NF-κB activation requires coordinated assembly of a regulatory
complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK.
Nat Immunol (2008) 9:1371–8. doi:10.1038/ni.1676
28. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family
member B cell-activating factor (BAFF) receptor-dependent and -independent
roles for BAFF in B cell physiology. J Immunol (2004) 173:2245–52.
29. Mayne CG, Amanna IJ, Hayes CE. Murine BAFF-receptor residues 168-175 are
essential for optimal CD21/35 expression but dispensable for B cell survival. Mol
Immunol (2009) 47:590–9. doi:10.1016/j.molimm.2009.09.010
30. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R. Estab-
lishment and characterization of BALB/c lymphoma lines with B cell properties.
J Immunol (1979) 122:549–54.
31. Bishop GA, Haughton G. Induced differentiation of a transformed clone of
Ly-1+ B cells by clonal T cells and antigen. Proc Natl Acad Sci U S A (1986)
83:7410–4. doi:10.1073/pnas.83.19.7410
32. Xie P, Hostager BS, Bishop GA. Requirement for TRAF3 in signaling by LMP1
but not CD40 in B lymphocytes. J Exp Med (2004) 199:661–71. doi:10.1084/
jem.20031255
33. Hostager BS, Bishop GA. Cutting edge: contrasting roles of TRAF2 and TRAF3 in
CD40-activated B lymphocyte differentiation. J Immunol (1999) 162:6307–11.
34. Hostager BS, Hsing Y, Harms DE, Bishop GA. Different CD40-mediated sig-
naling events require distinct CD40 structural features. J Immunol (1996)
157:1047–53.
35. Xie P, Hostager BS, Munroe ME, Moore CR, Bishop GA. Cooperation between
TRAFs 1 and 2 in CD40 signaling. J Immunol (2006) 176:5388–400.
36. Heath AW, Wu WW, Howard MC. Monoclonal antibodies to murine CD40
define two distinct functional epitopes. Eur J Immunol (1994) 24:1828–34.
doi:10.1002/eji.1830240816
37. Rowland SL, Tremblay MM, Ellison JM, Stunz LL, Bishop GA, Hostager BS. A
novel mechanism for TNFR-associated factor 6-dependent CD40 signaling. J
Immunol (2007) 179:4645–53.
38. Hildebrand JM, Luo Z, Manske MK, Price-Troska T, Ziesmer SC, Lin W, et al.
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF
recruitment and reveals new insights into BAFF-R signaling. J Exp Med (2010)
207:2569–79. doi:10.1084/jem.20100857
39. Li X,Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degra-
dation of TRAF2. Nature (2002) 416:345–7. doi:10.1038/416345a
40. Matsuzawa A, Tseng PH, Vallabhapurapu S, Luo JL, Zhang W, Wang H, et al.
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling
complex. Science (2008) 321:663–8. doi:10.1126/science.1157340
41. Amanna IJ, Dingwall JP, Hayes CE. Enforced bcl-xL gene expression restored
splenic B lymphocyte development in BAFF-R mutant mice. J Immunol (2003)
170:4593–600.
42. Mayne CG, Nashold FE, Sasaki Y, Hayes CE. Altered BAFF-receptor signaling
and additional modifier loci contribute to systemic autoimmunity in A/WySnJ
mice. Eur J Immunol (2009) 39:589–99. doi:10.1002/eji.200838569
43. Hatada EN, Do RK, Orlofsky A, Liou HC, Prystowsky M, MacLennan IC, et al.
NF-κB1 p50 is required for BLyS attenuation of apoptosis but dispensable for
processing of NF-κB2 p100 to p52 in quiescent mature B cells. J Immunol (2003)
171:761–8.
44. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, et al. BAFF-R,
a newly identified TNF receptor that specifically interacts with BAFF. Science
(2001) 293:2108–11. doi:10.1126/science.1061965
45. Madry C, Laabi Y, Callebaut I, Roussel J, Hatzoglou A, Le Coniat M, et al. The
characterization of murine BCMA gene defines it as a new member of the
tumor necrosis factor receptor superfamily. Int Immunol (1998) 10:1693–702.
doi:10.1093/intimm/10.11.1693
46. von Bulow GU, Russell H, Copeland NG, Gilbert DJ, Jenkins NA, Bram RJ. Mol-
ecular cloning and functional characterization of murine transmembrane acti-
vator and CAML interactor (TACI) with chromosomal localization in human
and mouse. Mamm Genome (2000) 11:628–32. doi:10.1007/s003350010125
47. Gibson TJ, Seiler M, Veitia RA. The transience of transient overexpression. Nat
Methods (2013) 10:715–21. doi:10.1038/nmeth.2534
48. Razani B, Zarnegar B, Ytterberg AJ, Shiba T, Dempsey PW, Ware CF, et al.
Negative feedback in non-canonical NF-kappaB signaling modulates NIK sta-
bility through IKKalpha-mediated phosphorylation. Sci Signal (2010) 3:ra41.
doi:10.1126/scisignal.2000778
49. Jin J, Xiao Y, Chang JH, Yu J, Hu H, Starr R, et al. The kinase TBK1 controls IgA
class switching by negatively regulating non-canonical NF-kappaB signaling.
Nat Immunol (2012) 13:1101–9. doi:10.1038/ni.2423
50. Hu H, Brittain GC, Chang JH, Puebla-Osorio N, Jin J, Zal A, et al. OTUD7B con-
trols non-canonical NF-kappaB activation through deubiquitination of TRAF3.
Nature (2013) 494:371–4. doi:10.1038/nature11831
51. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French DM, et al. BAFF/BLyS
receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface
loop and promotes processing of NF-kappaB2. Immunity (2002) 17:515–24.
doi:10.1016/S1074-7613(02)00425-9
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest. The editor declared a potential conflict of interest
to the main Topic Editor of this Research Topic, Dr. Linda Burkly, prior to han-
dling this paper because the author Joanne Hildebrand and the editor John Silke are
currently employed by the Walter and Eliza Hall Institute of Medical Research. Dr.
Burkly was satisfied that the potential for conflict was minor. The editor, John Silke,
now further declares that there has been no conflict of interest during the review
and handling of this manuscript.
Received: 16 September 2013; accepted: 07 December 2013; published online: 20
December 2013.
Citation: Lin WW, Hildebrand JM and Bishop GA (2013) A complex relationship
between TRAF3 and non-canonical NF-κB2 activation in B lymphocytes. Front.
Immunol. 4:477. doi: 10.3389/fimmu.2013.00477
This article was submitted to Inflammation, a section of the journal Frontiers in
Immunology.
Copyright © 2013 Lin, Hildebrand and Bishop. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | Inflammation December 2013 | Volume 4 | Article 477 | 12
